Effects of adalimumab therapy on disease activity and interferon-γ- mediated biochemical pathways in patients with rheumatoid arthritis

Autoimmunity

Volumn 44, Issue 3, 2011, Pages 235-242

  Kurz, Katharina ^a   Herold, Manfred ^a   Winkler, Christiana ^a   Klotz, Werner ^a   Russe, Elisabeth ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adalimumab; disease activity; neopterin; rheumatoid arthritis; tryptophan degradation

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALENDRONIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CALCIUM; CELECOXIB; COLECALCIFEROL; CYCLOSPORIN A; DICLOFENAC; ETIDRONIC ACID; FOLIC ACID; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IBUPROFEN; KYNURENINE; LEFLUNOMIDE; LEVOTHYROXINE SODIUM; LOSARTAN POTASSIUM; METHOTREXATE; METHYLPREDNISOLONE; METOPROLOL TARTRATE; NAPROXEN; NEOPTERIN; PANTOPRAZOLE; PREDNISOLONE; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; TRAMADOL; TRYPTOPHAN; UNINDEXED DRUG;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953108195     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2010.528476     Document Type: Article

References (38)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-281. (Pubitemid 32488705)
2. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005;11:S39-S44. (Pubitemid 40863818)
3. Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 2006;6: 13-19.
4. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-916. (Pubitemid 32224400)
5. Fairweather D, Cihakova D. Alternatively activated macro-phages in infection and autoimmunity. J Autoimmun 2009;33: 222-230.
6. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-1169.
7. Barrera P, Boerbooms AM, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PN, van de Putte LB, van der Meer JW. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070-1079. (Pubitemid 23229283)
8. Nassonov EL, Samsonov MY, Chichasova NV, Nikiphorova EL, Tilz GP, Demel U, Widner B, Fuchs D. Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:808-810. (Pubitemid 30487907)
9. Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. JRheumatol 1995;22:406-412.
10. Keystone EC, Snow KM, Bombardier C, Chang CH, Nelson DL, Rubin LA. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 1988;31:844-849.
11. Rubin LA, SnowKM, Kurman CC,Nelson DL, Keystone EC Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: Correlations with disease activity. J Rheumatol 1990;17:597-602. (Pubitemid 20201733)
12. Hannonen P, Tikanoja S, Hakola M, Mottonen T, Viinikka L, Oka M. Urinary neopterin index as a measure of rheumatoid activity. Scand J Rheumatol 1986;15:148-152. (Pubitemid 16048715)
13. Schroecksnadel K, Kaser S, Ledochowski M, Neurauter G, Mur E, Herold M, et al. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol 2003;30:1935-1939. (Pubitemid 37075539)
14. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 2006;25:334-337.
15. Pfefferkorn ER. Interferon gamma blocks the growth of toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984;81: 908-912. (Pubitemid 14197611)
16. Burke F, Knowles RG, East N, Balkwill FR. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer 1995;60: 115-122.
17. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of Tcell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-1372. (Pubitemid 29227522)
18. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol 2003;24: 242-248. (Pubitemid 36555962)
19. Chavele KM, Shukla D, Keteepe-Arachi T, Fuchs D, Pusey CD, Salama AD. Regulation of MPO-specific Tcell responses during disease remission in ANCA-associated vasculitis: The role of tregs, and tryptophan degradation. Arthritis Rheum 2010;62:1539-1548.
20. Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 2009;15: 1391-1396.
21. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-3412. (Pubitemid 41612206)
22. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42: 617-621. (Pubitemid 37220869)
23. van der Meer JW, Popa C, Netea MG. Side effects of anticytokine strategies. Neth J Med 2005;63(3):78-80. (Pubitemid 40403407)
24. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynur-enine by HPLC. Clin Chem 1997;43:2424-2426. (Pubitemid 28022985)
25. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metabol 2001;3:175-187.
26. Liang GC, Cordero M, Dyer A, Chang RW. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 2005;32:1662-1665. (Pubitemid 41324800)
27. Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, Nüsslein H, Woody J, Kalden JR, Manger B. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. JImmunol 1996;156:1646-1653.
28. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced trypto-phan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989;370:1063-1069. (Pubitemid 19230341)
29. Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, Brown RR, Proctor RA, Voss SD, Spriggs DR, Trump DL, Borden EC Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer 1992;69:562-571.
30. Shirey KA, Jung JY, Maeder GS, Carlin JM. Upregulation of IFN-gamma receptor expression by proinflammatory cyto-kines influences IDO activation in epithelial cells. J Interferon Cytokine Res 2006;26:53-62. (Pubitemid 43201737)
31. Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003; 42:541-548. (Pubitemid 36432473)
32. Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metallo-proteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol 2010;29:1301-1309.
33. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG; and the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndi-cate (BRAGGSS), Isaacs JD. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF-?B signalling pathways. Ann Rheum Dis 2010;69:1315-1320.
34. Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, vonBubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A. Systemic application of CpG-rich DNA suppresses adaptive T-cell immunity via induction of IDO. Eur J Immunol 2006;36: 12-20. (Pubitemid 43116387)
35. Szántó S, Koreny T, Mikecz K, Glant TT, Szekanecz Z, Varga J. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther 2007;9:R50.
36. Adams O, Besken K, Oberdörfer C, MacKenzie CR, Takikawa O, Däubener W. Role of indoleamine-2,3-dioxygen-ase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections. J Virol 2004;78: 2632-2636. (Pubitemid 38228963)
37. Couderc M, Payet S, Henquell C, Dubost JJ, Soubrier M. TNFalpha antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis. Joint Bone Spine 2010;77:414-417.
38. Van Doornum S, McColl G, Wicks IP Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005;44: 1428-1432. (Pubitemid 41631868)